Cancer Therapy with Nanoparticle-Medicated Intracellular Expression of Peptide CRM1-Inhibitor.
Sui, M., Xiong, M., Li, Y., Zhou, Q., Shen, X., Jia, D., Gou, M., Sun, Q.(2021) Int J Nanomedicine 16: 2833-2847
- PubMed: 33883894 
- DOI: https://doi.org/10.2147/IJN.S266398
- Primary Citation of Related Structures:  
6A38, 6A3A, 6A3B, 6A3C, 6A3E, 6KFT - PubMed Abstract: 
Peptides can be rationally designed as non-covalent inhibitors for molecularly targeted therapy. However, it remains challenging to efficiently deliver the peptides into the targeted cells, which often severely affects their therapeutic efficiency.
Organizational Affiliation: 
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, People's Republic of China.